Semaglutide vs Tirzepatide vs Retatrutide: Mechanisms, Trial Data, and EU Regulatory Status

Each receptor contributes a different piece of the metabolic phenotype. GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation contributes additional insulinotropic and adipose-tissue effects. Glucagon receptor activation, in the right balance, is associated with increased energy expenditure.^[7]

The clinical question is not 'more receptors equals better' in the abstract. It is whether the additional receptor activity translates into a meaningfully different outcome at acceptable tolerability in head-to-head or trial-program-quality comparisons.^[7]

Reported mean weight loss from the registration-grade trials, summarised at a glance: semaglutide STEP 1 reported around 14.9% mean weight loss at 68 weeks at 2.4 mg weekly; tirzepatide SURMOUNT-1 reported around 20.9% mean weight loss at 72 weeks at 15 mg weekly; the published phase 2 retatrutide trial reported around 24.2% mean weight loss at 48 weeks at 12 mg weekly. All three are placebo-controlled trial means in adults with obesity or overweight.^[5][6][4]

Read across the three numbers, but read carefully. The trials differ in duration, dose escalation, comparator arms, and inclusion criteria. Semaglutide STEP 1 ran to 68 weeks; SURMOUNT-1 ran to 72 weeks; the retatrutide phase 2 readout was at 48 weeks. Cross-trial comparisons are useful as a rough magnitude check, not as a precision ranking.^[7]

Single GLP-1 receptor agonist — Semaglutide. Mechanism: GLP-1 receptor only. Best-known phase 3 readout: STEP 1, ~14.9% mean weight loss at 68 weeks at 2.4 mg weekly. EU regulatory status: authorised. Authorised brands include Wegovy (chronic weight management) and Ozempic (type 2 diabetes), both with EMA EPARs.^[1][3][5]

Dual GIP and GLP-1 receptor agonist — Tirzepatide. Mechanism: GIP + GLP-1 receptors. Best-known phase 3 readout: SURMOUNT-1, ~20.9% mean weight loss at 72 weeks at 15 mg weekly. EU regulatory status: authorised. Authorised brand: Mounjaro, with an EMA EPAR.^[2][6]

Triple GIP, GLP-1, and glucagon receptor agonist — Retatrutide. Mechanism: GIP + GLP-1 + glucagon receptors. Best-known published readout: phase 2 NEJM trial, ~24.2% mean weight loss at 48 weeks at 12 mg weekly. EU regulatory status: not authorised. Sits in Eli Lilly's clinical pipeline at phase 2/3 development stage; no EMA EPAR has been issued.^[4][8]

Semaglutide and tirzepatide are not just 'molecules with good data'. They are authorised medicines with published EMA EPARs, summary of product characteristics, pharmacovigilance reporting requirements, and approved indications. That regulatory infrastructure is part of what 'available in Europe' actually means.^[1][2][3]

Retatrutide is at a different stage. It is in active development in Eli Lilly's clinical pipeline, with published phase 2 data and ongoing phase 3 programs at the time of writing, but it does not have an EMA marketing authorisation. Research-context products labelled 'retatrutide' should be described accordingly.^[4][8]

Any product page or comparison guide that flattens these regulatory differences — by, for example, listing all three as if they were equivalent off-the-shelf options — is hiding information that matters for an informed decision.^[10]

If 'best' means highest mean weight loss in a published registration-grade trial, the current order on those isolated numbers is retatrutide (phase 2) > tirzepatide (phase 3) > semaglutide (phase 3). But that ordering compresses three different things — receptor pharmacology, trial design, and evidence maturity — into one ranking it cannot actually support.^[5][6][4]

If 'best' means the medicine a prescriber should reach for, the answer depends on the indication (obesity vs type 2 diabetes), tolerability profile, comorbidities, regulatory availability, prescribing pathway, and patient preference. A systematic review can compare GLP-1 receptor agonists and polyagonists across these dimensions, but the personal choice still sits with the prescriber.^[7]

This article does not recommend a medicine, dose, or treatment route. A GLP-1 decision is a clinical decision.^[9]

A responsible GLP-1 hub should give buyers a clean map: what each molecule is, what each EMA EPAR says (where one exists), what the registration-grade trials report, and where the regulatory line sits between authorised medicines and research-context investigational compounds.^[1][2][4]

The product surface itself should keep mechanism, evidence stage, and quality proof clearly separated — and route readers to the goal page when they know the outcome they want, and to the product page when they know the molecule.^[11]